Peel Hunt Reiterates “Hold” Rating for Diploma (LON:DPLM)
Peel Hunt reaffirmed their hold rating on shares of Diploma (LON:DPLM) in a research note published on Monday morning, Stock Target Advisor reports.
A number of other analysts have also commented on the company. JPMorgan Chase & Co. reiterated an overweight rating and issued a GBX 1,739 ($22.72) price objective on shares of Diploma in a research report on Friday, August 30th. Royal Bank of Canada lifted their price objective on Diploma from GBX 1,280 ($16.73) to GBX 1,400 ($18.29) and gave the stock a sector performer rating in a research report on Thursday, August 22nd. Seven equities research analysts have rated the stock with a hold rating, The company currently has an average rating of Hold and an average target price of GBX 1,490 ($19.47).
DPLM stock traded down GBX 5 ($0.07) during midday trading on Monday, reaching GBX 1,770 ($23.13). The stock had a trading volume of 150,198 shares, compared to its average volume of 128,194. The business has a fifty day simple moving average of GBX 1,655 and a two-hundred day simple moving average of GBX 1,562.34. The firm has a market cap of $2.00 billion and a price-to-earnings ratio of 34.71. Diploma has a twelve month low of GBX 1,144 ($14.95) and a twelve month high of GBX 1,954 ($25.53).
The business also recently announced a dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Thursday, November 28th will be given a dividend of GBX 20.50 ($0.27) per share. This is a positive change from Diploma’s previous dividend of $8.50. This represents a dividend yield of 1.15%. The ex-dividend date of this dividend is Thursday, November 28th. Diploma’s payout ratio is presently 0.51%.
Diploma Company Profile
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in North America, Europe, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies consumables and instruments for the diagnostic testing of blood, tissue, and other samples in hospital pathology and life sciences laboratories; electrosurgery and minimally invasive surgery equipment and consumables for use in hospital operating rooms; and surgical medical devices, and related consumables and services to GI endoscopy suites in hospitals and private clinics.
Further Reading: 52-week highs
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.